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Introduction {#sec1}
============

SARS-CoV-2, the causative agent of COVID-19, causes significant mortality and morbidity worldwide and was declared a pandemic by the World Health Organization in March, 2020 ([@bib8]). The rapid spread of the virus has caused not only a significant health care burden but also an economic crisis. Governments around the world have introduced strict social distancing measures to keep transmission under control. However, a vaccine will ultimately be required to fully suppress the SARS-CoV-2 pandemic. A wide variety of vaccine designs are being developed against SARS-CoV-2, and there has been promising preclinical and clinical efficacy data published for at least four different vaccine candidates ([@bib13]; [@bib16]; [@bib37]; [@bib40]).

Messenger RNA (mRNA)-based vaccines have recently demonstrated great promise in the fight against infectious diseases ([@bib1]). One of the most widely studied of these vaccine platforms uses antigen-encoding nucleoside-modified mRNA encapsulated into lipid nanoparticles (mRNA-LNP) ([@bib27]). Nucleoside-modified mRNA-LNP vaccines have induced protective immune responses against various pathogens in preclinical studies ([@bib4]; [@bib10]; [@bib12]; [@bib24]; [@bib28], [@bib29], [@bib31]; [@bib32]; [@bib33]), in many cases, after administration of a single dose ([@bib12]; [@bib28], [@bib29], [@bib31]). This vaccine type has been shown to elicit particularly strong CD4^+^ T cell, germinal center B cell and long-lived plasma cell responses associated with durable, protective neutralizing antibody responses ([@bib21]; [@bib29]). Of note, a very limited amount of published human clinical data are available on the safety and efficacy of mRNA-LNPs ([@bib5]; [@bib11]), and no mRNA vaccines for humans have been licensed to date.

In this study, we assessed the immunogenicity of two nucleoside-modified mRNA-LNP vaccines targeting the spike (S) glycoprotein of SARS-CoV-2: one is encoding the full-length S protein with deleted furin cleavage site and the other is encoding the S protein receptor binding domain (RBD). We evaluated immune responses after a single intramuscular (i.m.) injection with the SARS-CoV-2 mRNA-LNP or control vaccines in BALB/c mice. We found that both mRNA vaccines induced potent CD4^+^ and CD8^+^ T cell responses in the spleen and lung. Moreover, we measured strong long-lived plasma cell and memory B cell responses associated with high titers of neutralizing antibodies. Importantly, our nucleoside-modified (1-methylpseudouridine-containing) SARS-CoV-2 mRNA-LNP vaccines are very similar to clinical vaccine candidates utilized by Moderna Therapeutics ([@bib16]) and BioNTech RNA Pharmaceuticals in partnership with Pfizer ([@bib26]); thus, we believe that the studies described within this manuscript may inform ongoing clinical trials and the design of future human trials.

Results {#sec2}
=======

*In Vitro* Characterization of SARS-CoV-2 Nucleoside-Modified mRNA Constructs {#sec2.1}
-----------------------------------------------------------------------------

We designed and produced mRNAs encoding three potential SARS-CoV-2 vaccine antigens: full-length S protein (wild-type \[WT\]), full-length S protein with a deleted furin cleavage site (Δfurin), and a short construct encoding the soluble RBD of S protein. The Δfurin mutant was included as a potential way to stabilize the full-length S and to maintain the covalent association of the S1 and S2 subunits ([@bib20]), while the RBD was investigated as it is a critical target of neutralizing antibodies against SARS-CoV-2. Protein expression from mRNAs was confirmed by *in vitro* cell transfection studies. RBD protein secretion was demonstrated by ELISA using supernatant from RBD mRNA-transfected 293F cells ([Figure 1](#fig1){ref-type="fig"} A). Because the full-length WT and Δfurin S proteins contain the transmembrane domain, they were expressed on the surface of transfected 293F cells. Thus, we used flow cytometry to assess binding of full-length WT and Δfurin S proteins by an anti-RBD monoclonal antibody, D001, and a human ACE2-Fc (hACE2-Fc) fusion protein. Interestingly, we found that the full-length Δfurin S protein showed higher binding capacity to D001 and hACE2-Fc compared to its WT counterpart, indicating that it may be a better vaccine antigen, due either to higher expression or favorable antigenicity ([Figure 1](#fig1){ref-type="fig"}B). Therefore, we selected the full-length Δfurin construct to evaluate in immunization studies along with RBD.Figure 1*In Vitro* Characterization of SARS-CoV-2 Nucleoside-Modified mRNA Constructs(A) Supernatant from 293F cells transfected with RBD-encoding mRNA or mock was tested for binding reactivity to D001 and hACE2-Fc by ELISA. Data shown are area under curve of the log-transformed concentrations (log AUC). Symbols represent independent experiments.(B) 293F cells were transfected with mRNA encoding SARS-CoV-2 full-length WT and Δfurin S protein. Binding reactivity of full-length WT and Δfurin S proteins to D001, hACE2-Fc, and negative control CH65 (an anti-influenza neutralizing antibody) was measured by flow cytometry. Binding capacity was expressed in mean fluorescence intensity (MFI). Each dot represents an independent experiment. p value indicates a paired t test; ^∗^p \< 0.05. Data represent mean plus SEM.

SARS-CoV-2 mRNA Vaccines Induce Strong T Cell Responses in the Spleen and Lungs {#sec2.2}
-------------------------------------------------------------------------------

BALB/c mice were injected with a single i.m. dose of 30 μg of mRNA-LNPs encoding full-length Δfurin, RBD, or firefly luciferase (Luc, negative control) mRNA-LNPs, and S protein-specific CD4^+^ and CD8^+^ T cell responses were evaluated after 10 days by intracellular cytokine staining ([Figures 2](#fig2){ref-type="fig"} , [S1](#mmc1){ref-type="supplementary-material"}, and [S2](#mmc1){ref-type="supplementary-material"}). Both spike mRNA constructs elicited antigen-specific, polyfunctional CD8^+^ ([Figure 2](#fig2){ref-type="fig"}A) and CD4^+^ ([Figure 2](#fig2){ref-type="fig"}B) T cells expressing type 1 (Th1) immune response cytokines (interferon \[IFN\]-γ, tumor necrosis factor \[TNF\], and interleukin \[IL\]-2) as well as CD8^+^ T cells with cytotoxic markers (granzyme B^+^ CD107a^+^) ([Figure 2](#fig2){ref-type="fig"}C) in both the spleen and lungs. These responses were particularly robust in the lungs, especially for CD8^+^ T cells. We also noted that the vast majority of the CD8^+^ T cell response in BALB/c mice was directed at epitopes in the N-terminal half of the S protein, while CD4^+^ T cells recognized epitopes in both halves of the protein ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Because S protein-specific lung-infiltrating T cell responses may contribute to SARS-CoV-2 vaccine protection as seen with SARS-CoV-1 ([@bib42]), we next examined whether vaccine-induced lung T cells were truly infiltrating into the lung parenchyma. We performed intravenous (i.v.) labeling with a CD45-specific antibody in order to differentiate between vascular (i.v. label-positive) and tissue-infiltrating (i.v. label-negative) lung CD4^+^ and CD8^+^ T cells ([Figures 2](#fig2){ref-type="fig"}D--2G, [S1](#mmc1){ref-type="supplementary-material"}C, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D). SARS-CoV-2 mRNA-LNP vaccines elicited significant increases in activated (CD69^+^ or PD-1^+^) and antigen-experienced (CD44^+^CD62L^−^) CD8^+^ and CD4^+^ T cells that were tissue-infiltrating, with comparatively modest increases in the vasculature, suggesting that activated vaccine-induced T cells readily exit the vasculature and enter the lung parenchyma ([Figures 2](#fig2){ref-type="fig"}D--2G, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D). Of note, in each of the above assays, we found that the full-length Δfurin vaccine induced greater T cell responses compared to the RBD vaccine; this might be explained by the presence of additional T cell epitopes in the longer protein product produced by the full-length Δfurin construct.Figure 2SARS-CoV-2 mRNA Vaccines Induce S Protein-Specific Type 1 Cellular ResponsesBALB/c mice were vaccinated i.m. with a single dose of 30 μg of mRNA-LNP vaccines.(A--C) Spleen and lungs were harvested and stimulated with SARS-CoV-2 S protein peptide pools 10 days after immunization. (A) CD8^+^ and (B) CD4^+^ T cells were stained for type 1 intracellular cytokine expression and (C) CD8^+^ T cells for cytolytic markers granzyme B and CD107a as well.(D--G) Cells were stained directly *ex vivo* for activation markers, showing the proportion of i.v.-label negative (tissue-"infiltrating") and i.v.-label positive ("vascular") T cells that are (D and E) CD69^+^ and (F and G) CD44^+^ CD62L^−^ in lung. n = 8 mice per vaccine group and n = 5 naive mice, pooled from two independent experiments. Naive mice were age matched, non-immunized BALB/c mice. (C--G) Symbols represent individual animals. Data shown are mean plus SEM. Statistical analysis: (A--C) Kruskal-Wallis and post hoc Mann-Whitney U tests with Bonferroni correction and (D--G) two-way repeated-measures ANOVA test with multiple post hoc comparisons with Dunnett's correction. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

SARS-CoV-2 mRNA Vaccines Elicit Potent and Sustained Humoral Immune Responses without *In Vitro* Antibody-Dependent Enhancement Activity {#sec2.3}
----------------------------------------------------------------------------------------------------------------------------------------

Mice were immunized i.m. with a single dose of 30 μg of full-length Δfurin, RBD, and Luc mRNA-LNPs, and antibody responses were evaluated. Both SARS-CoV-2 vaccines induced high levels of S protein-specific IgG by 4 weeks post immunization, and IgG titers further increased by week 9 ([Figure 3](#fig3){ref-type="fig"} A). Using a vesicular stomatitis virus (VSV)-based pseudovirus neutralization assay, we demonstrated that nucleoside-modified SARS-CoV-2 mRNA-LNP vaccines induced high and sustained levels of neutralizing antibodies after administration of a single vaccine dose, with week 9 sera showing higher neutralization activity than week 4 ([Figure 3](#fig3){ref-type="fig"}B). Importantly, induction of antibodies with high neutralization titers was also demonstrated by microneutralization assay using live SARS-CoV-2 with week 9 post immunization samples ([Figure 3](#fig3){ref-type="fig"}C). Both assays indicated that the full-length Δfurin mRNA-LNPs generated slightly higher levels of neutralizing antibodies than the RBD vaccine at 9 weeks post immunization ([Figures 3](#fig3){ref-type="fig"}B and 3C). Importantly, the levels of neutralization we observed are similar to those mediated by SARS-CoV-2 immune human convalescent plasma samples analyzed by the same laboratory in the same assay format ([@bib3]).Figure 3Humoral Immune Responses after SARS-CoV-2 mRNA VaccinationBALB/c mice received a single i.m. immunization with 30 μg of SARS-CoV-2 or Luc mRNA-LNP vaccines.(A and B) S protein-specific IgG levels were determined by endpoint dilution ELISA (A) and neutralizing antibody (Nab) levels were measured by a VSV-based pseudovirus neutralization assay (B) before immunization and 4 and 9 weeks post immunization.(C) Nab levels were further confirmed by microneutralization assay using serum obtained 9 weeks post vaccination. n = 10 mice/group. Naive mice were age matched, non-immunized BALB/c mice. (A--C) Symbols represent individual animals. Horizontal lines represent the limit of detection. End-point dilution ELISA, FRNT~50~, and IC~50~ titers below the limit of detection are reported as half of the limit of detection. Data shown are mean plus SEM.(D) HEK293T cells transfected to express mFcγR1 were infected with SARS-CoV-2 pseudovirus or ZIKV virus-like particles preincubated with serially diluted anti-SARS-CoV-2 sera obtained 9 weeks post immunization or anti-ZIKV sera, respectively. Serum samples were pooled from 5 mice belonging to the same experimental group. Infection level was measured by luciferase assays. Mean ± SEM of three independent experiments is presented. Statistical analysis: (A and B) two-way ANOVA and (C) one-way ANOVA with Tukey's multiple comparison on log-transformed data. (D) SARS-CoV-2: there are no significant differences when analyzed by two-way ANOVA with Tukey's multiple comparisons test; ZIKV: two-way ANOVA with Sidak's multiple comparisons test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Antibody-dependent enhancement (ADE) of infection by virus-specific antibodies is a potential serious concern for several vaccines including those for Zika and dengue viruses and coronaviruses ([@bib36]). Thus, we investigated whether or not the SARS-CoV-2 mRNA vaccine-elicited antibodies induced ADE of infection in HEK293T cells expressing mouse FcγR1 (mFcγR1-293T cells). We demonstrated that none of the mRNA-vaccinated mouse immune sera mediated SARS-CoV-2 ADE under *in vitro* conditions. As a positive control to validate the mFcγR1-293T cells as generally susceptible to ADE, we show robust ADE of Zika virus (ZIKV) infection by sera derived from ZIKV-infected mice ([Figure 3](#fig3){ref-type="fig"}D) using the same system. Although ADE assays are typically conducted in the absence of the bona fide viral entry receptor, to examine whether the viral receptor affects ADE efficiency, cells expressing hACE2 as well as mFcγR1 were also used in ADE assays. SARS-CoV-2 pseudovirus infection of hACE2/mFcγR1-293T cells was efficiently neutralized as expected by sera derived from mice vaccinated with the full-length Δfurin or RBD mRNAs at low dilutions ([Figure S3](#mmc1){ref-type="supplementary-material"}), and there was no enhanced infection observed at any serum dilution. As in the mFcγR1-293T cells, ZIKV-immune mouse sera mediated robust ADE in the hACE2/mFcγR1-293T cells. These results demonstrate that neither the full-length Δfurin nor RBD mRNA-LNP vaccines generate antibodies with mFcγR1-dependent ADE activity *in vitro*.

SARS-CoV-2 mRNA Vaccines Induce Strong Long-Lived Plasma Cell and Memory B Cell Responses {#sec2.4}
-----------------------------------------------------------------------------------------

Most successful vaccine approaches rely on the generation of memory B cells (MBC) and long-lived plasma cells (LLPC) ([@bib34]). While MBCs can mount rapid recall responses upon a secondary exposure, LLPCs residing in the bone marrow contribute to protection from infection by a persistent production of antigen-specific antibodies. To examine the magnitude and quality of antigen-specific LLPC and MBC responses, mice were immunized i.m. with a single dose of 30 μg of full-length Δfurin, RBD, or Luc mRNA-LNPs and sacrificed 9 weeks post vaccination ([Figures 4](#fig4){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}). Splenic full-length S protein and RBD-specific IgG1 ([Figures 4](#fig4){ref-type="fig"}A, 4D, 4F, [S4](#mmc1){ref-type="supplementary-material"}A, and S4C) and IgG2a/b ([Figures 4](#fig4){ref-type="fig"}B, 4E, 4G, and [S4](#mmc1){ref-type="supplementary-material"}C) expressing MBCs were identified by flow cytometry. Of note, we found that a single immunization with the SARS-CoV-2 mRNA vaccines resulted in the generation of antigen-specific class-switched MBCs. We also observed a significant increase of full-length S protein and RBD-specific IgM B cells ([Figures S4](#mmc1){ref-type="supplementary-material"}B--S4D). To assess antigen-specific LLPC responses, bone marrow was collected from vaccinated mice, and the number of full-length S protein and RBD-specific antibody secreting cells (ASC) was determined ([Figures 4](#fig4){ref-type="fig"}H and 4I). Both SARS-CoV-2 mRNA vaccines induced high levels of antigen-specific ASCs after administration of a single vaccine dose. Various subsets of RBD-specific Ig-producing cells were further characterized by ELISPOT ([Figure 4](#fig4){ref-type="fig"}J). We found that ASCs primarily produce antigen-specific IgG1, IgG2a, and IgG2b.Figure 4SARS-CoV-2 mRNA Vaccines Elicit Antigen-Specific MBC and LLPC ResponsesBALB/c mice received a single i.m. immunization with 30 μg of SARS-CoV-2 or Luc mRNA-LNP vaccines and sacrificed 9 weeks post immunization.(A and B) Representative flow cytometry staining of full-length Δfurin and RBD-specific splenic (A) IgG1 and (B) IgG2a/2b memory B cells (MBC).(C) Quantification of total splenic RBD-specific MBC.(D and E) Quantification of splenic full-length Δfurin-specific (D) IgG1 and (E) IgG2a/2b MBC.(F and G) Quantification of RBD-specific splenic (F) IgG1 and (G) IgG2a/2b MBC.(H and I) Quantification of bone marrow (H) RBD and (I) full-length Δfurin-specific IgG antibody secreting cells (ASC).(J) Quantification of bone marrow RBD-specific IgG1, IgG2a, IgG2b, IgG3, IgM and IgA ASCs. n = 10 mice per group, pooled from two independent experiments. Naive mice were age-matched, non-immunized BALB/c mice. Symbols represent individual animals. Data shown are mean plus SEM. Statistical analysis: one-way ANOVA with Bonferroni correction, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

The rapid spread of COVID-19 has caused a global health tragedy and significant economic loss. Safe, effective, and widely available vaccines could end the pandemic; thus, generating such vaccines is an urgent unmet clinical need. Currently, multiple SARS-CoV-2 vaccine candidates are under development using conventional immunogens (live attenuated virus, inactivated virus, and adjuvanted protein subunit vaccines), as well as viral and genetic (DNA and mRNA) approaches ([@bib2]). mRNA-based vaccines are among the lead candidates because they have been shown to be generally highly effective in small and large animal models ([@bib30]) and have additional beneficial features over other vaccine platforms. First, mRNA is non-infectious, cannot integrate into the genome, and incorporation of modified nucleosides into the mRNA sequence along with proper purification ([@bib6]; [@bib18], [@bib19]; [@bib39]) can decrease its inflammatory capacity; thus mRNA vaccines may have a stronger safety profile than virus-based (potentially integrating, replicating, or contagious) vaccine platforms. Second, mRNA vaccine antigens can be very rapidly designed and produced, as illustrated by Moderna Therapeutics who produced a SARS-CoV-2 nucleoside-modified mRNA-LNP vaccine for human use in just 42 days after obtaining the sequence of the target antigen. Third, nucleoside-modified mRNA-LNP vaccines have been demonstrated to induce extremely potent and protective immune responses against other viruses after administration of a single dose in animal models ([@bib28], [@bib29], [@bib31]). If reproducible in humans, this one-time immunization feature of the vaccine platform would be particularly important in a pandemic or epidemic setting, by inducing immune protection after a single point-of-care visit.

Despite active research, no peer-reviewed preclinical studies have been published on nucleoside-modified SARS-CoV-2 mRNA-LNP vaccines to date. Here, we provide a detailed evaluation of two nucleoside-modified SARS-CoV-2 mRNA-LNP vaccine formulations (full-length Δfurin and RBD) in mice. Animals were immunized only once in all experiments presented in this study. Both the full-length Δfurin and RBD mRNA vaccines induced potent CD4^+^ and CD8^+^ T cell responses, particularly in the lungs. The production of Th1 cytokines was strong, with approximately one half of detectable S protein-specific CD4^+^ T cells producing the hallmark Th1 cytokine IFN-γ, along with a high frequency of IFN-γ-producing CD8^+^ T cells. This result is noteworthy, as a major safety consideration of SARS-CoV-2 vaccine design is the elicitation of a strong Th1-biased immune response, instead of a Th2-biased response that might induce vaccine-associated enhanced respiratory disease (VAERD) ([@bib14]). A potential protective role of lung-homing T cells has been suggested by the SARS-CoV-1 literature ([@bib42]) and prompted us to examine T cell responses in the lung. Interestingly, we found that S protein-specific CD4^+^ and CD8^+^ T cell responses were substantially higher in the lung compared to the spleen, leading us to hypothesize that T cells raised by this format of nucleoside-modified mRNA-LNP vaccine may preferentially home to the lungs, or at least to mucosal surfaces in general. Probing further, we found that a large fraction of these cells could be detected in the lung parenchyma, indicating that these cells might be well positioned to contribute to immune protection. Future studies should examine the role of T cells in immune protection from SARS-CoV-2 infection and diseases, particularly at later time points.

Induction of long-lived plasma cells (LLPCs) and memory B cells (MBCs) is very important to achieve durable protective humoral immune responses ([@bib34]). We found that both SARS-CoV-2 mRNA-LNP vaccines elicited potent LLPC and MBC responses, as well as the rapid generation of neutralizing antibodies that persisted at a high level until at least week 9 after immunization. ADE of disease results from antibody-mediated enhancement of infection, which has been described for some flaviviruses ([@bib9]) and has been raised as a potential concern for coronaviruses. ADE has only been demonstrated in *in vitro* studies for SARS-CoV-1 ([@bib17]); thus, it is uncertain if it poses a substantial risk in the setting of SARS-CoV-2. We demonstrated that neither mRNA-LNP vaccine elicited antibodies with ADE activity in *in vitro* experiments. Thus, we reason that ADE may not be a critical safety issue for SARS-CoV-2 mRNA-based vaccines, although this assumption needs to be directly investigated in future *in vivo* (animal) experiments and may differ between animals and humans.

Nucleoside-modified mRNA-LNP vaccines for SARS-CoV-2 are currently under clinical development by Moderna ([@bib16]) and Pfizer/BioNTech ([@bib26]). A recent publication provided preliminary data from a clinical phase I dose-escalation study led by Moderna ([@bib16]). The company used a nucleoside-modified mRNA-LNP vaccine platform (similar or identical to ours) encoding SARS-CoV-2 spike stabilized in its prefusion conformation and immunized participants two times each with 25, 100, or 250 μg of mRNA. In agreement with our mouse data, they found that nucleoside-modified mRNA-LNPs induced Th1-biased T cell responses and robust humoral immune responses in people. Adverse events included typical local and systemic reactions, were clearly dose-dependent, and were typically worse following the second immunization. A second nucleoside-modified mRNA-LNP vaccine platform (also similar or identical to ours), encoding the SARS-CoV-2 spike receptor binding domain and developed by Pfizer/BioNTech, was recently shared as a pre-print and showed similar dose-dependent immunogenicity and adverse events ([@bib26]). The data presented here could potentially inform the evaluation of these two vaccines in humans. For example, our data prompt the question of whether these vaccines would induce T cells that home to the airways in humans and whether these might contribute to protection from COVID-19 disease or otherwise alter the inflammatory environment during SARS-CoV-2 infection. Finally, our observation of strong CD8^+^ T cell responses with cytotoxic markers suggests a potentially important way that mRNA-LNP vaccines may differ from protein subunit and inactivated virus vaccines, which are not expected to generate strong CD8^+^ T cell responses. However, it remains to be seen whether CD8^+^ T cell responses, lung-resident or otherwise, contribute meaningfully to immune protection in SARS-CoV-2 animal models or in humans.

Limitations of Study {#sec3.1}
--------------------

Our study has some limitations, the most critical one being the absence of protective efficacy studies that could assess whether our nucleoside-modified mRNA-LNP vaccines induce protection from SARS-CoV-2 viral replication or disease in an animal model. We were unable to perform these studies in the BALB/c mouse model used here, because BALB/c mice are not susceptible to robust SARS-CoV-2 replication or disease. Instead, transgenic mice carrying the human angiotensin-converting enzyme 2 (hACE2) gene are a more appropriate animal model for future protective efficacy studies for SARS-CoV-2 ([@bib7]; [@bib23]). Another suitable mouse model was recently reported ([@bib15]), involving the intranasal delivery of an adenoviral vector encoding hACE2 to WT mice prior to viral challenge. These useful tools were not available as of the time of this publication but are the subject of ongoing and future protection studies.

One key consideration for human SARS-CoV-2 vaccines is to determine the ideal vaccine dose and vaccination schedule. While important, our study was not designed to address this dose optimization question. Additionally, it is unclear how mouse vaccine doses can be extrapolated to human immunization, i.e., whether it is at all proportional to body weight or affected by immunogenetic differences between species. As a result, the dose and schedule will likely need to be optimized through human clinical trials. The major aim of our studies was to provide detailed analyses of immune responses to two nucleoside-modified SARS-CoV-2 mRNA vaccines in mice as a proof-of-principle that may guide the exploration of similar mRNA-LNP vaccines in human clinical trials. We used a single immunization of 30 μg mRNA-LNPs in these studies because we found that this vaccine dose induced durable protective immune responses against other viruses in mice ([@bib29]; [@bib28]; [@bib31]). In agreement with previous studies, we demonstrated that a single immunization with 30 μg of nucleoside-modified SARS-CoV-2 vaccines elicited potent T and B cell responses and generated high and sustained levels of neutralizing antibodies in 100% of mice. In future experiments, it may be useful to systematically scale down dosing in order to determine the minimal protective dose after one or two immunizations. However, as cautioned above, this would require confirmation in non-human primate models or human clinical trials.

Because no other peer-reviewed preclinical experiments are available on SARS-CoV-2 nucleoside-modified mRNA-LNP vaccines, we believe that our work will provide valuable information about the magnitude and quality of immune responses induced by this new and promising vaccine type and will inform ongoing and future clinical trials.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Fixable Viability Dye eFluor780eBioScience65-0865-14CD3 clone 17A2, APC-Fire750Biolegend100248Ter-119 clone Ter-119, APC-Fire750Biolegend116250CD19 clone 6D5, BV605Biolegend115540B220 clone RA3-6B2, Alexa Fluor 700eBioScience56-0452-82CD38 clone 90, PE-Cy7Biolegend102718FAS clone JO2, BV510BD Biosciences563646IgG1 clone A85-1, V450BD Biosciences562107IgG2a/2b clone R2-40, Brilliant Blue 700BD Biosciences745969IgM polyclonal, FITCJackson ImmunoResearch115-095-020IgG polyclonal, HRPJackson ImmunoResearch115-035-003IgM polyclonal, biotinSouthern Biotech1020-08Igκ polyclonal, biotinSouthern Biotech1050-08Igλ polyclonal, biotinSouthern Biotech1060-08IgG1 polyclonal, biotinSouthern Biotech1070-08IgG2a polyclonal, biotinSouthern Biotech1080-08IgG2b polyclonal, biotinSouthern Biotech1090-08IgG3 polyclonal, biotinSouthern Biotech1100-08IgA clone RMA-1, biotinBiolegend400703B220 clone RA36B2, BUV496BD Biosciences612950CD19 clone ID3, BUV661BD Biosciences612971CD138 clone 281-2, BUV737BD Biosciences564430PD-L2 clone TY25, BV711BD Biosciences740818CD4 clone H129.19, PE-Cy5BD Biosciences553654CD8α clone 53-6.7, PE-Cy5BD Biosciences553034CD86 clone GL-1, BV421Biolegend105031CXCR4 clone I.276F12, PE-Dz594Biolegend146514IgD clone 11-26c.2a, APC-Cy7Biolegend405716GL7 clone GL-7, AF488Biolegend144612streptavidin, BV650Biolegend405231Ter-119 clone Ter-119, PE-Cy5eBioScience15-5921-82F4/80 clone BM8, PE-Cy5eBioScience15-4801-82CD73 clone TY/11.8, PE-Cy7eBioScience25-0731-82CD38 clone 90 AF700Invitrogen56-0381-82anti-RBD chimeric monoclonal antibody, D001Sino Biologicals40150-D001anti-human IgG Fc secondary antibody, PEInvitrogen12-4998-82LIVE/DEAD Fixable Aqua Dead Cell Stain KitInvitrogenL34966CD45 clone 30-F11 Alexa Fluor 700Biolegend103128Live/Dead AquaThermo FisherL34957CD16/CD32 clone 2.4G2bioXcellBE0307CD3, clone 145-2C11, APC-Cy7BD Biosciences557596CD4 clone RM4-5, Pacific BlueBiolegend100531CD8, clone 53-6.7 PerCP-Cy5.5BD Biosciences551162PD-1 clone RMP1-30, APCBiolegend109112CD69 clone H1.2F3, BV605Biolegend104530CD44, clone IM7, BV785Biolegend103059CD62L clone MEL-14, PE-Cy7Biolegend104418CD28 clone 37.51Tonbo40-0281-M001CD107a clone 1D4B, Alexa Fluor 647Biolegend121610CD4 clone RM4-5, BV786BD Biosciences563727CD8 clone 53-6.7, BUV395BD Biosciences563786IFN gamma clone XMG1.2, Alexa Fluor 488Biolegend505813TNF alpha clone MP6-XT22, BV605Biolegend506329IL-2 clone JES6-5H4, PEBiolegend503808granzyme B clone GB11, Pacific BlueBiolegend515408anti-guinea pig IgG FcJackson ImmunoResearch106-035-008anti-human IgG FcSigma-AldrichI2136rabbit anti-RBD antibody R007Sino Biologicals40150-R007anti-rabbit IgG H&L, HRPAbcam97080anti-mouse IgG, HRPJackson ImmunoResearch715-035-150anti-VSV Indiana GAbsolute AntibodyAb01401-2.0SARS-CoV-1 nucleoprotein antibodyThomas MoranN/A**Chemicals and Recombinant Protein**m1-pseudouridine-5′-triphosphateTriLinkN-1081CleanCapTriLinkN-7413CelluloseSigma-Aldrich11363-250GRecombinant RBD and Full SpikeFlorian Krammer and Raffael NachbagauerN/ASARS-CoV-2 spike peptide poolsJPTPM-WCPV-Sbrefeldin ABiolegend420601monensinBiolegend420701Cytofix/Cytoperm kitBD Biosciences554714ELISPOT AEC Substrate SetBD Biosciences551951BCIP/NBTSigmaB1911-100mLKPL TMB 2-Component Microwell Peroxidase SubstrateSeracare5120-0050SureBlue Reserve TMB 1-Component Microwell Peroxidase SubstrateSeracare5120-0083Luc-Pair Firefly Luciferase HS Assay KitGenecopoeiaLF007Luc-Pair Renilla Luciferase HS Assay KitGenecopoeiaLF010TransIT-mRNA Transfection KitMirusMIR 2250Collagenase DSigma11088866001ACK Lysing bufferLonza10-548ELightning-Link® R-PhycoerythrinExpedeon336-0005Lightning-Link (R) Rapid Alexa Fluor 647Expedeon703-0010BD Brilliant BufferBD Biosciences563794ExpiFectamine 293 transfection kitGIBCOA14525Ni-NTA resinQIAGEN30230Bradford reagentBio-Rad5000201**Experimental Models: Organisms/Strains**BALB/c mouse (T cell studies)Jackson LaboratoryN/ABALB/c mouse (all other studies)Charles River LaboratoriesN/A**Experimental Models: Cell Lines**HEK293T/17 cellsATCCCRL11268FreeStyle 293 (293F) cellsGIBCOR79007Vero E6 cells stably expressing TMPRSS2Dr. Stefan PohlmannN/A**Bacterial and Virus Strains**SARS-CoV-2GenBankMT020880ZIKVStrain PB-81N/A**Recombinant DNA**pCMV-SPORT6-mFcγR1DharmaconMMM1013-202708624SARS-CoV-2 S proteinGenBankMN908947.3SARS-CoV-2 S delta18Dr. Stefan PohlmannN/AZIKV replicon (FSS13025)GenBankKU955593.1**Softwares and Algorithms**S6 FluoroSpot AnalyzerCTLN/AFlowJo softwareFlowJo LLCN/AFACSDIVA softwareBD BiosciencesN/AGraphPad PrismGraphPadN/A

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for supporting data, resources, and reagents should be directed to and will be fulfilled upon request by the Lead Contact, Norbert Pardi (<pnorbert@pennmedicine.upenn.edu>).

### Materials Availability {#sec4.2.2}

Reagents from this study are available upon request.

### Data and Code Availability {#sec4.2.3}

The source of protein and nucleic acid sequences are indicated in the manuscript and are available from the corresponding author on request.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

BALB/c mice aged 8 weeks were purchased from Jackson Laboratory (T cell studies), or Charles River Laboratories (all other studies).

### Cell lines {#sec4.3.2}

FreeStyle 293 (293F) cells (GIBCO \#R79007) were cultured in Freestyle 293 Expression Medium (GIBCO). The 293F cell line was tested for mycoplasma contamination after receipt from Life Technologies and before expansion and cryopreservation.

HEK293T/17 cells (ATCC \#CRL11268) were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Mediatech \#MT10-013-CM) containing 10% fetal calf serum (FCS). Vero E6 cells stably expressing TMPRSS2 were a gift from Stefan Pohlman and were cultured in DMEM +10% FCS.

Method Details {#sec4.4}
--------------

### Ethics statement {#sec4.4.1}

The investigators faithfully adhered to the "Guide for the Care and Use of Laboratory Animals" by the Committee on Care of Laboratory Animal Resources Commission on Life Sciences, National Research Council. Mouse studies were conducted under protocols approved by the Institutional Animal Care and Use Committees (IACUC) of the University of Pennsylvania (UPenn), BIOQUAL Inc. (Rockville, MD), and the Children's Hospital of Philadelphia (CHOP). All animals were housed and cared for according to local, state and federal policies in an Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)-accredited facility.

### mRNA-LNP vaccine production {#sec4.4.2}

mRNA vaccines were designed based on the SARS-CoV-2 spike (S) protein sequence (Wuhan-Hu-1, GenBank: MN908947.3). Coding sequences of full length WT S protein, full length Δfurin S protein (RRAR furin cleavage site abolished between amino acids 682-685), RBD (amino acids 1-14 fused with amino acids 319-541) and firefly luciferase (Luc) were codon-optimized, synthesized and cloned into the mRNA production plasmid as described ([@bib12]). mRNA production and LNP encapsulation was performed as described ([@bib12]). Briefly, mRNAs were transcribed to contain 101 nucleotide-long poly(A) tails. m1Ψ-5′-triphosphate (TriLink \#N-1081) instead of UTP was used to generate modified nucleoside-containing mRNA. Capping of the *in vitro* transcribed mRNAs was performed co-transcriptionally using the trinucleotide cap1 analog, CleanCap (TriLink \#N-7413). mRNA was purified by cellulose (Sigma-Aldrich \# 11363-250G) purification, as described ([@bib6]). All mRNAs were analyzed by agarose gel electrophoresis and were stored frozen at −20°C. Cellulose-purified m1Ψ-containing RNAs were encapsulated in LNPs using a self-assembly process as previously described wherein an ethanolic lipid mixture of ionizable cationic lipid, phosphatidylcholine, cholesterol and polyethylene glycol-lipid was rapidly mixed with an aqueous solution containing mRNA at acidic pH ([@bib22]). The RNA-loaded particles were characterized and subsequently stored at −80°C at a concentration of 1 μg μl^-1^. The mean hydrodynamic diameter of these mRNA-LNP was \~80 nm with a polydispersity index of 0.02-0.06 and an encapsulation efficiency of \~95%. Two or three batches from each mRNA-LNP formulations were used in these studies and we did not observe variability in vaccine efficacy.

### mRNA transfection {#sec4.4.3}

293F cells were diluted to 1 × 10^6^ cells/ml before transfection. 3 μg mRNA encoding full length WT and Δfurin S protein was transfected into 6 mL of cells. For soluble RBD, 30 mL of cells were transfected with 15 μg mRNA. TransIT-mRNA Transfection Kit (Mirus \#MIR 2250) was used for mRNA transfection following the manufacturer's instructions. Transfected cells were cultured at 37°C with 8% CO~2~ and shaking at 130 rpm for 48 hours (for full length WT and Δfurin S protein) or 72 hours (for soluble RBD).

### Sample processing and flow cytometry {#sec4.4.4}

#### In vitro studies {#sec4.4.4.1}

Binding reactivity of anti-RBD chimeric mAb, D001 (Sino Biologicals \#40150-D001) and hACE2-Fc fusion protein to full length S protein constructs (WT and Δfurin) was measured by flow cytometry. Briefly, mRNA-transfected 293F cells were harvested 48 hours after transfection and were washed once with 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS). Next, cells were incubated with 10 μg/ml D001 or hACE2-mFc in V-bottom 96-well plates for 30 minutes at 4°C. Cells were then incubated with goat anti-human IgG Fc secondary antibody, PE (Invitrogen \#12-4998-82) at final concentration of 2.5 μg/ml for 30 minutes at 4°C in dark. Following this, dead cells were stained with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen \#L34966, used at 1:1000 in PBS) for 15 minutes at 4°C in dark, then washed twice and re-suspended with 1% BSA in PBS. Flow cytometric data were acquired on a LSRII with high-throughput system using FACSDIVA software (BD Biosciences).

#### T cell studies {#sec4.4.4.2}

*In vivo antibody labeling:* to distinguish lung-infiltrating and vascular T cells, mice were injected intravenously under isoflurane anesthesia with 2 μg of anti-CD45 Alexa Fluor 700 antibody (Biolegend \#103128). After 5 minutes, mice were euthanized via cervical dislocation and organs were collected for analysis.

*Lung and spleen isolation for flow cytometry*: to isolate lung lymphocytes, the lung vasculature was first perfused with 5 mL 1% fetal bovine serum (FBS) in PBS by injecting into the cardiac right ventricle. Lungs were collected in gentleMACS C tubes containing 1% FBS in PBS on ice. Digest media was added to achieve a final concentration of 2.25 mg/ml sterile-filtered Collagenase D (Sigma \#11088866001) and 0.15 mg/ml DNase I in 4 mL of 1% FBS in PBS. Lungs were disrupted using gentleMACS Dissociator program m_spleen_01.01, then incubated for 45 minutes at 37°C with shaking. Ten ml of complete RPMI media (10% FBS, 2 mM L-glutamine, 50 μM 2-mercaptoethanol, and penicillin/streptomycin) was then added to each tube, followed by further homogenization using gentleMACS Dissociator program m_lung_02.01. Digested lungs were then passed through a 70 μm strainer, incubated in ACK lysis buffer to remove RBCs, then passed through a 40 μm strainer to obtain a single cell suspension. Spleens were collected in PBS and homogenized through a 70 μm cell strainer using the hard end of a syringe plunger. Splenocytes were incubated in ACK lysis buffer to remove red blood cells (RBCs), then passed through a 40 μm strainer to obtain a single cell suspension.

*T cell activation analysis:* after preparing lung and spleen single cell suspensions, cells were immediately analyzed for activation markers. Cells were stained with Live/Dead Aqua (Thermo Fisher \#L34957) in PBS, followed by Fc-receptor blockade with anti-CD16/CD32 (bioXcell \#BE0307), and then stained for 30 minutes at 4°C with the following antibody panel each at 1:100 in 0.1% BSA in PBS: anti-CD3 APC-Cy7 (BD Biosciences \#557596), anti-CD4 Pacific Blue (Biolegend \#100531), anti-CD8 PerCP-Cy5.5 (BD Biosciences \#551162), anti-PD-1 APC (Biolegend \#109112), anti-CD69 BV605 (Biolegend \#104530), anti-CD44 BV785 (Biolegend \#103059), anti-CD62L PE-Cy7 (Biolegend \#104418). Samples were analyzed on the CytoFLEX LX flow cytometer (Beckman Coulter).

*Intracellular cytokine staining:* to measure antigen-specific T cells, 1 million cells per well of lung or spleen cells were stimulated with SARS-CoV-2 spike peptide pools (JPT PM-WCPV-S) in a U-bottom plate for at 37°C, 6% CO~2~ with 2 μg/ml anti-CD28 (Tonbo \#40-0281-M001) providing co-stimulation. Vial 1 (N-terminal) and vial 2 (C-terminal) of spike peptides were dissolved in DMSO at 666 μg/ml per peptide and used separately at a final concentration of 1.5 μg/ml. Stimulations proceeded for 1 hour before adding 5 μg/ml brefeldin A (Biolegend \#420601), 2 μM monensin (Biolegend \#420701), and 5 μg/ml anti-CD107a Alexa Fluor 647 (Biolegend \#121610) for 5 hours more. DMSO served as a negative control and the combination of 50 μg/ml phorbol 12-myristate 13-acetate and 1 μg/ml ionomycin served as a positive control. After a total of 6 hours, samples were kept \< 4°C and stained with Live/Dead Aqua and anti-CD16/CD32 blockade as above, fixed and permeabilized using the Cytofix/Cytoperm kit (BD Biosciences \#554714), and stained intracellularly for 1 hour in 0.1% BSA in PBS with antibodies including (each at 2 μg/ml): anti-CD3 APC-Cy7 (BD Biosciences \#557596), anti-CD4 BV786 (BD Biosciences \#563727), anti-CD8 BUV395 (BD Biosciences \#563786), anti-IFN gamma Alexa Fluor 488 (Biolegend \#505813), anti-TNF BV605 (Biolegend \#506329), anti-IL-2 (Biolegend \#503808), and anti-granzyme B Pacific Blue (Biolegend \#515408). Samples were analyzed on the Aurora flow cytometer (Cytek).

#### B cell studies {#sec4.4.4.3}

*Sample Processing:* spleens were mashed in complete DMEM \[(Corning \#T10014CV) containing 10% heat inactivated Fetal Bovine Serum (FBS Corning \#35-015), 1% Glutamax (GIBCO \#35050-061) and 1% Penicillin/Streptomycin (GIBCO \#5070063)\] on ice and filtered through a 40 μm cell strainer. RBCs were lysed with ACK Lysing buffer (Lonza \#10-548E) for 5 minutes on ice and the reaction was stopped with ten times the volume PBS. Bone marrow (BM) was harvested from femurs and tibia from each mouse using a 23.5g X ¾" needle and syringe into FACS buffer and filtered through a 63 μm Nitex mesh. RBCs were lysed in ACT buffer for 5 minutes on ice. After RBC lysis, splenocytes and BM cells were resuspended in cold media and immediately used for cell counting, culture or staining.

*Staining and flow* *cytometry*: single cell suspensions of murine splenocytes were incubated with anti-CD16/CD32 (BioXCell \#BE0307) in FACS buffer (PBS with 2% heat inactivated FBS) prior to staining with all surface anti-mouse antibodies, labeled recombinant proteins (probes) and viability dye for 30 minutes at 4°C. Recombinant SARS-CoV-2 Receptor Binding Domain (RBD) or Full length S proteins were independently conjugated to both R-PE and Alexa Fluor 647 using Lightning-Link® R-Phycoerythrin (R-PE) (Expedeon \#336-0005) and Lightning-Link (R) Rapid Alexa Fluor 647 (Expedeon \#703-0010) kits according to the manufacturer's instructions. For immunophenotyping of antigen-specific memory B cells (MBC), splenocytes were stained with: anti-mouse CD19 BV605 (Biolegend \#115540), B220 AF700 (eBioScience \#56-0452-82), CD3 APC-Fire750 (Biolegend \#100248), Ter119 APC-Fire750 (Biolegend \#116250), CD38 PE-Cy7 (Biolegend \#102718), FAS BV510 (BD Biosciences \#563646), IgG1 eFluor450 (BD Biosciences \#562107), and IgG2a/2b BB700 (BD Biosciences \#745969) and IgM FITC (Jackson ImmunoResearch \#115-095-020) antibodies, together with RBD- or full length S-PE, RBD- or full length S AlexaFluor 647, and Fixable Viability Dye eFluor780 (eBioscience \#115-095-020). The excess of antibodies were washed away with FACS buffer and cells were fixed with 1% paraformaldehyde (PFA) for 30 minutes at 4°C prior to acquisition on a 5 laser Cytoflex LX (Beckman Coulter).

Alternatively, MBC were assessed without respect to isotype as follows: 5 million splenocytes or BM cells were prepared as above stained with fixable live dead aqua (Biolegend Zombie Aqua \#423101) for 15 minutes at room temperature. Cells were then washed with FACS buffer and stained with the following dilutions of antibodies: B220-BUV496 (BD Biosciences \#612950), CD19-BUV661 (BD Biosciences \#612971), CD138-BUV737 (BD Biosciences \#564430), PD-L2-BV711 (BD Biosciences \#740818), CD4-PE-Cy5 (BD Biosciences \#553654), CD8α-PE-Cy5 (BD Biosciences \#553034), CD86-BV421 (Biolegend \#105031), IgA-biotin (Biolegend \#400703), CXCR4-PE-Dz594 (Biolegend \#146514), IgD-APC-Cy7 (Biolegend \#405716), GL7-AF488 (Biolegend \#144612), SA-BV650 (Biolegend \#405231), Ter-199-PE-Cy5 (eBioScience \#15-5921-82), F4/80-PE-Cy5 (eBioScience \#15-4801-82), CD73-PE-Cy7 (eBioScience \#25-0731-82), and CD38-AF700 (Invitrogen \#56-0381-82) in BD Brilliant Buffer (BD Biosciences \#563794) for 15 minutes at 4°C. Cells were then washed and stained streptavidin BV650 for 10 minutes at 4°C prior to wash and resuspension in FACS buffer. \~2 million events per sample were acquired on a BD Symphony A3 Lite.

All flow cytometry data were analyzed with FlowJo software (FlowJo LLC).

### Full-length S and RBD protein production {#sec4.4.5}

The RBD and full-length S proteins were produced in 293F cells, as described previously ([@bib3]; [@bib38]). Briefly, 600 million cells were transfected with 200 μg of purified DNA encoding codon-optimized RBD of SARS-CoV-2 using ExpiFectamine 293 transfection kit (GIBCO \#A14525). The manufacturer's protocol was followed and cells were harvested on day 3. Cells were spun at 4000 g for 10 minutes and sterile-filtered with a 0.22 μm filter. Supernatant was incubated with Ni-NTA resin (QIAGEN \#30230) for 2 hours. After 2 hours, this mixture was loaded onto columns and the protein was eluted using elution buffer with high amounts of imidazole. Protein was concentrated using 10 kDa Amicon centrifugal units (Millipore Sigma \#UFC901024) and re-constituted in PBS. Concentration was measured using Bradford reagent (Bio-Rad \#5000201) and a reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was run to check the integrity of the protein.

### ELISPOT assay {#sec4.4.6}

MultiScreenHTS IP Filter Plate, 0.45 μm (Millipore Sigma \#MSIPS4W10) were coated overnight at 4°C with 2.5 μg/ml recombinant SARS-CoV-2 RBD or Full Spike proteins in bicarbonate buffer (35 mM NaHCO~3~ and 15 mM Na~2~CO~3~). Plates were washed three times with PBS and blocked with complete DMEM for at least 1 hour at 37°C. Single cell suspensions of murine BM cells were diluted serially in complete DMEM with halving dilutions starting at 1 × 10^6^ cells. Following overnight incubation at 37°C and 5% CO~2~, plates were washed three times with 0.05% Tween-20 in PBS. Membranes were incubated with IgG-HRP (Jackson ImmunoResearch \#115-035-003) diluted in complete DMEM for 2 hours at room temperature. Following incubation with the detection antibody, plates were washed three times with 0.05% Tween-20 in PBS. Spots corresponding to antigen-specific antibody-secreting cells were developed using BD ELISPOT AEC Substrate Set (\#551951) and counted using a CTL Immunospot analyzer. Isotype specific ELISPOT plates were coated and incubated with cells as above and then were washed 4x with 0.1% Tween-20 in PBS. Membranes were then incubated with 1:3000 isotype-specific biotinylated antibodies (Southern Biotech \#1020-08, \#1050-08, \#1060-08, \#1080.08, \#1090-08, \#1100-08, Biolegend \#400703) for 1 hour. Membranes were then washed 4x and incubated in 1:20,000 streptavidin-alkaline phosphatase (Sigma \# E2636) for 30 minutes. Membranes were then washed 4x and incubated with 50 μL BCIP/NBT (Sigma \#B1911-100mL) for \~10 minutes or until spots developed at which time reaction was quenched with 100 μL 1M sodium phosphate monobasic solution. Membranes were then dried and counted above.

### Mouse immunizations {#sec4.4.7}

mRNA-LNPs were diluted in PBS and injected into the gastrocnemius muscle (40 μL injection volume) with a 3/10cc 29½G insulin syringe (Covidien \#8881600145).

### Blood collection {#sec4.4.8}

Blood was collected from the orbital sinus under isoflurane anesthesia. Blood was centrifuged for 5 minutes at 13,000 rpm and the serum was stored at −20°C and used for ELISA, virus neutralization assays, and ADE assays.

### Enzyme linked immunosorbent assay (ELISA) {#sec4.4.9}

#### Samples from cell transfections {#sec4.4.9.1}

Supernatant from 293F cells transfected with RBD-encoding mRNA was harvested 72 hours after transfection and concentrated 60x with Vivaspin 20 kDa molecular weight cut-off concentrator (GE Healthcare \#20-9323-60). The expression and binding of soluble RBD were measured by indirect ELISA. RBD samples were added to capture antibody D001 (2 μg/ml)-coated plates for one hour, followed by detection with serum from a SARS-CoV S protein-immunized guinea pig for 1 hour. Serum binding was detected via horseradish peroxidase-conjugated goat anti-guinea pig IgG (Fc) (Jackson ImmunoResearch \#106-035-008, used at 1:10,000). Plates were developed with SureBlue Reserve TMB 1-Component Microwell Peroxidase Substrate (Seracare \#5120-0083). Absorbance at 450 nm were measured by a SpectraMax Plus 384 microplate reader (Molecular Devices) and log area under curve (logAUC) were calculated.

To test RBD sample binding to ACE2, plates were first coated with goat anti-human IgG (Fc) antibody (Sigma-Aldrich \#I2136) (2 μg/ml), in order to capture the hACE2-mFc construct (5 μg/ml, one hour). Next, the RBD samples were incubated for one hour. The RBD was detected by a rabbit anti-RBD antibody R007 (Sino Biologicals \#40150-R007, used at 1:4000) followed by Goat Anti-Rabbit IgG H&L (HRP) (Abcam \#97080). The detection of RBD and development procedure were the same as described above.

#### Samples from mouse immunizations {#sec4.4.9.2}

Corning 96 Well Clear Polystyrene High Bind Stripwell Microplates (Corning \#2592) were coated with 1 μg/ml purified RBD in PBS overnight at 4°C. The plates were blocked with 2% BSA in PBS for 2 hours and washed four times with wash buffer (0.05% Tween-20 in PBS). Mouse sera were diluted in blocking buffer and incubated for 2 hours at room temperature, followed by four washes. HRP-conjugated anti-mouse secondary antibody (Jackson Immunoresearch \#715-035-150) was diluted 1:10,000 in blocking buffer and incubated for 1.5 hours, followed by 4 washes. KPL 2-component TMB Microwell Peroxidase Substrate (Seracare \#5120-0050) was applied to the plate and the reaction was stopped with 2 N sulfuric acid. The absorbance was measured at 450 nm using a SpectraMax 190 microplate reader. RBD-specific IgG end-point dilution titer was defined as the highest dilution of serum to give an OD greater than the sum of the background OD plus 0.01 units. All samples were run in technical duplicates.

### Pseudovirus neutralization assay {#sec4.4.10}

Production of VSV pseudotype with SARS-CoV-2 S: 293T cells plated 24 hours previously at 5 X 10^6^ cells per 10 cm dish were transfected using calcium phosphate with 35 μg of pCG1 SARS-CoV-2 S delta18 expression plasmid encoding a codon optimized SARS-CoV S gene with an 18 residue truncation in the cytoplasmic tail (kindly provided by Stefan Pohlmann). Twelve hours post transfection the cells were fed with fresh media containing 5mM sodium butyrate to increase expression of the transfected DNA. Thirty hours after transfection, the SARS-CoV-2 spike expressing cells were infected for 2-4 hours with VSV-G pseudotyped VSVΔG-RFP at an MOI of \~1-3. After infection, the cells were washed twice with media to remove unbound virus. Media containing the VSVΔG-RFP SARS-CoV-2 pseudotypes was harvested 28-30 hours after infection and clarified by centrifugation twice at 6,000 g then aliquoted and stored at −80°C until used for antibody neutralization analysis.

Antibody neutralization assay using VSVΔG-RFP SARS-CoV-2: Vero E6 cells stably expressing TMPRSS2 were seeded in 100 μL at 2.5x10^4^ cells/well in a 96 well collagen coated plate. The next day, 2-fold serially diluted serum samples were mixed with VSVΔG-RFP SARS-CoV-2 pseudotype virus (50-200 focus forming units/well) and incubated for 1 hour at 37°C. Also included in this mixture to neutralize any potential VSV-G carryover virus was 8G5F11, a mouse anti-VSV Indiana G, at a concentration of 100 ng/ml (Absolute Antibody \#Ab01401-2.0). The antibody-virus mixture was then used to replace the media on VeroE6 TMPRSS2 cells. 20 hours post infection, the cells were washed and fixed with 4% PFA before visualization on an S6 FluoroSpot Analyzer (CTL, Shaker Heights OH). Individual infected foci were enumerated and the values compared to control wells without antibody. The focus reduction neutralization titer 50% (FRNT~50~) was measured as the greatest serum dilution at which focus count was reduced by at least 50% relative to control cells that were infected with pseudotype virus in the absence of mouse serum. FRNT~50~ titers for each sample were measured in two technical replicates performed on separate days.

### Microneutralization assay {#sec4.4.11}

Neutralization assays with live SARS-CoV-2 (USA-WA1/2020; GenBank: MT020880) were performed in a biosafety level 3 (BSL3) facility with strict adherence to institutional regulations. Twenty thousand Vero.E6 cells per well were seeded in a 96-well cell culture plate one day before the neutralization assay and this protocol has been published earlier ([@bib3]). Mouse serum samples were heat-inactivated at 56°C for 1 hour. Various dilutions of the serum samples in duplicates were prepared in 1X minimal essential medium (MEM) supplemented with FBS and each dilution was mixed with 600 TCID~50~ of SARS-CoV-2 for 1 hour at room temperature. Cell culture medium from Vero.E6 cells was removed and each dilution was added to the 96-well plate. Cells were incubated with this serum-virus mixture for 1 hour at 37°C. After 1 hour, the serum-virus mixture was removed, and the same respective dilutions were added with an equal amount of 1X MEM supplemented with 2% FBS. Cells were incubated for 48 hours at 37°C after which cells were fixed with 10% formaldehyde. Following fixation for 24 hours at 4°C, cells were stained with a SARS-CoV-1 nucleoprotein antibody (mouse 1C7, obtained from Dr. Thomas Moran, Icahn School of Medicine at Mount Sinai). Further details have been described earlier ([@bib3]). Each plate had six controls wells that were not infected and six wells that were infected but had no serum. The background from uninfected control wells was averaged and subtracted from all the wells. Percent inhibition at each well was calculated by the following formula: 100-(((X-\[average of "no virus" wells\])/\[average of "virus only" wells\])^∗^100) whereby 'X' is the read for each well. Non-linear regression curve fit analysis over the dilution curve was performed to calculate IC~50~.

### SARS-CoV-2 pseudovirus (PV) and Zika virus (ZIKV) virus-like particle (VLP) production {#sec4.4.12}

SARS-CoV-2 PV was produced as previously described ([@bib25]) with a minor modification. HEK293T cells were transfected by calcium-phosphate transfection method at a ratio of 5:5:1 with a plasmid encoding murine leukemia virus (MLV) gag/pol proteins, a retroviral vector pQCXIX expressing firefly luciferase, and a plasmid expressing the spike protein of SARS-CoV-2 (GenBank YP_009724390). Cells were washed 6 hours later, and the culture supernatant containing PV was harvested at 43 hours post transfection. ZIKV VLP was produced by transfecting HEK293T cells by the calcium transfection method with a ZIKV replicon (strain FSS13025, GenBank [KU955593.1](ncbi-n:KU955593.1){#intref0015}), whose expression is controlled by tetracycline, a plasmid encoding ZIKV capsid, prM, and E proteins (strain FSS13025, GenBank [KU955593.1](ncbi-n:KU955593.1){#intref0020}), and the pTet-On plasmid expressing a reverse Tet-responsive transcriptional activator (rtTA) at a ratio of 2:1:1. Cells were washed 6 hours later and replenished with fresh media containing 1 μg/ml Doxycycline. The VLP-containing culture supernatant was harvested 48 hours post transfection. ZIKV replicon was generated by replacing the region spanning 39th through 763rd amino acids of the polyprotein of a ZIKV molecular clone ([@bib41]) with Renilla luciferase with the 2A self-cleaving peptide fused at its C terminus. This construct contains the tetracycline-responsive P~tight~ promoter that derives ZIKV RNA transcription. The PV- and VLP-containing culture supernatants were cleared by 0.45 μm filtration and immediately frozen in aliquots at −80°C.

### Antibody-dependent enhancement (ADE) assay {#sec4.4.13}

The ability of SARS-CoV-2 immune sera to mediate ADE was measured using HEK293T cells or those stably expressing hACE2 transfected with pCMV-SPORT6-mFcγR1 (Dharmacon \#MMM1013-202708624). Mouse immune sera used for ADE assays were obtained 9 weeks post vaccination or from naive mice. Sera of ten mice per vaccine group were pooled in two groups (five per pool) and assessed separately in ADE assays but combined afterward for data analysis. We have previously shown efficient ZIKV ADE ([@bib35]), and thus used ZIKV VLP as a positive control in ADE assays. ZIKV immune sera were prepared by intraperitoneally injecting mice with ZIKV (strain PB-81) and bled at 5 weeks post infection. The immune and naive sera samples, heat inactivated for 30 minutes at 56°C, were serially diluted in DMEM containing 10% heat-inactivated FBS. SARS-CoV-2 PV expressing firefly luciferase or ZIKV VLP expressing Renilla luciferase in 50 μL was preincubated for 1 hour at 37°C with 50 μL of diluted plasma and added to cells plated on the 96 well plates. Twenty four hours later, infection levels were assessed using Luc-Pair Firefly Luciferase HS Assay Kit (Genocopia \#LF007) for SARS2-CoV-2 PV and Luc-Pair Renilla Luciferase HS Assay Kit (Genocopia \#LF010) for ZIKV VLP.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

GraphPad Prism was used to perform Kruskal-Wallis and Mann-Whitney tests for non-parametric data and one-way or two-way ANOVA corrected for multiple comparisons for parametric data to compare immune responses in vaccinated and control mice.
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